Frank de Vries


Prof. Frank de Vries started a PhD in pharmaco-epidemiology at Utrecht University in 2002 on side effects of use of inhaled corticosteroids. Since then, he has worked for the Medicine and Healthcare products Regulatory Agency. He has obtained several research grants and prizes, including the Swierenga award for respiratory disease, an NWO Veni grant and the Kohn prize from the UK National Osteoporosis Foundation. His work has been published in various journals including JAMA, the NEJM and BMJ. He is on secondment at the Utrecht Institute for Pharmaceutical Sciences, the Netherlands. He is a visiting scientist at the MRC Lifecourse Epidemiology Unit in Southampton, UK. Frank works as a hospital pharmacist in the Maastricht UMC+,

Frank’s current research activities mainly focus on effects of drugs in patients with diabetes mellitus and movement disorders. As the department’s head of research, he oversees other research lines on personalised medicine in the areas of lung oncology and psychiatric disorders.

Department of Clinical Pharmacy & Toxicology
P. Debyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht
T: +31(0)43 387 18 81

  • 2020
    • Werkman, N. C. C., Nielen, J. T. H., van den Bergh, J. P. W., Ejskjaer, N., Røikjer, J., Schaper, N. C., Rossi, B., Klungel, O., Vestergaard, P., de Vries, F., & Driessen, J. H. M. (2020). Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. Current Drug Safety, 15(1).
    • de Bruin, I. J. A., Wyers, C. E., Souverein, P. C., van Staa, T. P., Geusens, P. P. M. M., van den Bergh, J. P. W., de Vries, F., & Driessen, J. H. M. (2020). The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK. Osteoporosis International, 31(8), 1487-1497.
    • Abtahi, S., Burden, A. M., Geusens, P., van den Bergh, J. P., van Staa, T., & de Vries, F. (2020). The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. Journal of the American Medical Directors Association, 21(6), 811-816.
    • Oortgiesen, B. E., Driessen, J. H. M., Hoogendoorn, M., Kibbelaar, R. E., Veeger, N. J. G. M., van den Bergh, J. P. W., Vestergaard, P., de Vries, F., & van Roon, E. N. (2020). No decrease in fracture risk despite 15 years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study. Bone, 134, [115299].
    • de Vries, F. (2020). Letter regarding "Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning". Neuro-oncology, 22(4), 580-581.
    • van Veelen, A., van Geel, R., de Beer, Y., Dingemans, A-M., Stolk, L., Ter Heine, R., de Vries, F., & Croes, S. (2020). Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results. Biomedical Chromatography, 34(4), [e4771].
    • Keene, S. J., Adab, P., de Vries, F., Franssen, F. M. E., Sitch, A., Martin, J., Marshall, T., & Jordan, R. (2020). The stability of the ADO score among UK COPD patients from The Health Improvement Network. ERJ Open Research, 6(1), [196].
    • Nielen, J. T. H., Driessen, J. H. M., Dagnelie, P. C., Boonen, A., van den Bemt, B., van Onzenoort, H. A. W., Neef, C., Henry, R. M. A., Burden, A. M., Sep, S. J. S., van der Kallen, C. J., Schram, M. T., Schaper, N., Stehouwer, C. D. A., Smits, L., & de Vries, F. (2020). Drug utilization in the Maastricht Study: A comparison with nationwide data. Medicine, 99(1), [18524].
    • Houghton, R., de Vries, F., & Loss, G. (2020). Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder. Cns Drugs, 34(1), 93-101.
  • 2019
    • van Herpen-Meeuwissen, L. J. M., van den Bemt, B. J. F., Derijks, H. J., van den Bemt, P. M. L. A., de Vries, F., Maat, B., & van Onzenoort, H. A. W. (2019). Economic impact of Patient's Own Medication use during hospitalisation: a multicentre pre-post implementation study. International Journal of Clinical Pharmacy, 41(6), 1658-1665.